السمنة غير المحددة عندما لا يحقق علاج نمط الحياة والعلاج السلوكي فقدان الوزن المستهدف

References

DOI: 10.2337/dc26-S008

• Obesity pharmacotherapy should be considered for people with diabetes and overweight or obesity along with lifestyle changes.
• In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide), especially considering their added weight-independent benefits.
• Obesity pharmacotherapy should be initiated at the lowest dose and the dose titration based on tolerability and response.
• Gradual stepwise uptitration of obesity medications is a well-supported clinical strategy used in clinical trials for enhancing drug tolerability, reducing adverse effects, and optimizing medication-taking behavior.
• Those who achieve sufficient early weight loss upon starting a chronic obesity pharmacotherapy (typically defined as >5% weight loss after 3 months of use) should continue the medication long-term.